It concerns the use radiopharmaceuticals of formula (I) in diagnosing Alzheimer' disease. In particular it concerns the radiopharmaceuticals, which are able to pass through the blood-brain barrier and bind to the CCR1 receptor present in brain tissue of patients having Alzheimer's disease.
Radiopharmaceuticals for diagnosing Alzheimer's disease